

## Special Issue

# B Cells and Antibodies in Immune Surveillance and Therapy for Cancer

### Message from the Guest Editors

A better understanding of the role of B cells in orchestrating an antitumor response has the potential to broaden the efficacy of immunotherapy for patients with advanced cancer. This Special issue will summarize several topics related to humoral antitumor immunity, including the dual role of B cells in promoting and inhibiting cancer, the antitumor functions of B cells such as antibody-dependent cell cytotoxicity, mechanisms of tumor-antigen presentation by B cells, the importance of cancer-associated tertiary lymphoid structures, and the impact of immunoglobulin repertoire and isotype on cancer immunosurveillance. Finally, we will assemble an up-to-date review on recent advances in developing B cell-based immunotherapies and vaccines for the treatment of advanced cancers.

### Guest Editors

Prof. Dr. Sophia Karagiannis

St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, London SE1 9RT, UK

Dr. Joseph G Crompton

Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA

### Deadline for manuscript submissions

closed (15 December 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/95735](https://mdpi.com/si/95735)

*Cancers*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)